Children's Growth Hormone Testing: Clinical Methods, Sample Requirements, and Diagnostic Applic

Children's growth hormone (GH) testing is a specialized laboratory evaluation used to diagnose growth hormone deficiency and other pediatric growth disorders through measurement of basal and stimulated GH levels alongside related biomarkers such as IGF-1 and IGFBP-3. Because GH secretion is highly pulsatile, accurate testing requires carefully controlled sampling protocols and validated immunoassay methods performed in accredited clinical laboratories. This article provides a comprehensive technical overview of the sample types, testing items, analytical methods, and clinical applications involved in children's growth hormone testing.

Technical Overview

Growth hormone (GH), also known as somatotropin, is a 191-amino-acid, 22-kDa single-chain polypeptide hormone secreted by the somatotroph cells of the anterior pituitary gland. It is the principal hormonal driver of linear growth in children, acting both directly on growth plates and indirectly through the stimulation of insulin-like growth factor 1 (IGF-1), which is produced primarily in the liver. GH secretion is regulated by the opposing actions of growth hormone-releasing hormone (GHRH) and somatostatin from the hypothalamus.

A defining characteristic of GH physiology is its pulsatile secretion pattern. The hormone is released in 6 to 12 discrete pulses over a 24-hour period, with the largest surge occurring during slow-wave (deep) sleep, and it exhibits a short plasma half-life of approximately 15 to 30 minutes. This pulsatility creates the central analytical challenge of GH testing: a single random GH measurement cannot reliably distinguish deficient from normal secretion. Consequently, pediatric GH evaluation relies on a combination of basal hormone measurement, dynamic stimulation (provocation) testing, and downstream biomarkers such as IGF-1 and IGFBP-3.

Growth hormone deficiency (GHD) affects approximately 1 in 3,500 to 4,000 children and is a significant cause of short stature, defined as a height more than 2 standard deviations below the population mean for age and sex. Early and accurate diagnosis is critical because recombinant human GH (rhGH) replacement therapy is most effective when initiated before epiphyseal closure. All analytical work supporting this diagnostic pathway should be performed in laboratories operating under recognized quality frameworks, such as ISO 15189 for medical laboratories or ISO/IEC 17025 for general testing competence, with assay calibrators traceable to international reference materials and procedures compliant with applicable GB and ISO standards.

Testing Samples

Serum

Serum collected from venous whole blood is the standard specimen for GH, IGF-1, and IGFBP-3 measurement. A fasting morning venipuncture is recommended to reduce variability from nutritional and circadian influences. Blood should be drawn into serum separator tubes, allowed to clot completely at room temperature, and centrifuged within two hours of collection. Serum is stable at 2–8°C for 24 to 48 hours; for longer storage, aliquots should be frozen at −20°C or below and protected from repeated freeze–thaw cycles. Grossly hemolyzed, lipemic, or icteric samples should be rejected as they may interfere with immunoassay signal detection.

Plasma

Plasma collected in EDTA anticoagulant tubes is acceptable on many automated immunoassay platforms, provided the manufacturer's specimen claim includes plasma. Plasma tubes should be inverted gently, centrifuged promptly, and handled under the same temperature conditions as serum. Heparinized plasma may be used on some systems but can occasionally cause assay interference; laboratory validation per ISO 15189 method-verification requirements is necessary before accepting alternative matrix types.

Serial Samples for Provocation Testing

Dynamic GH stimulation tests require an indwelling intravenous catheter through which multiple timed blood specimens are drawn, typically at baseline (0 minutes) and then at 30-minute or defined intervals over 90 to 120 minutes depending on the pharmacological agent used. The highest value across the series is reported as the peak stimulated GH. Each specimen must be clearly labeled with the collection time, processed identically, and analyzed in a single analytical run whenever possible to minimize inter-assay variability.

Dried Blood Spots

Dried blood spot specimens are used in some research settings and epidemiological studies for IGF-1 screening, offering minimally invasive sampling and stable transport at ambient temperature. Their use in routine diagnostic GH assessment remains limited and should follow validated, fit-for-purpose protocols.

Testing Items

The diagnostic evaluation of growth disorders in children integrates several laboratory and auxiliary parameters, each contributing distinct diagnostic information:

• Basal (random) serum GH – a single fasting measurement, primarily useful as a screening indicator; low basal values are expected in healthy children due to pulsatile secretion and are not diagnostic of deficiency.
• Peak stimulated GH – the definitive laboratory endpoint obtained during pharmacological provocation testing; a peak below the laboratory-defined cutoff (commonly below 10 ng/mL, or below 7 ng/mL in more stringent protocols) after two separate stimulation tests supports a diagnosis of GH deficiency.
• Insulin-like growth factor 1 (IGF-1, somatomedin C) – the principal downstream effector of GH action; age-, sex-, and puberty-standardized IGF-1 values provide an integrated reflection of GH secretion over preceding days and are essential for both diagnosis and therapy monitoring.
• Insulin-like growth factor binding protein 3 (IGFBP-3) – the major circulating carrier protein for IGF peptides; it is less nutrition-dependent than IGF-1, exhibits a longer half-life, and is particularly informative in children under five years of age.
• Auxological and imaging correlates – growth velocity calculations, height standard deviation scores, bone age radiographs (Greulich–Pyle or Tanner–Whitehouse methods), and pituitary MRI, which together support laboratory findings and identify organic causes such as craniopharyngioma or pituitary hypoplasia.

Testing Methods

Pharmacological Stimulation Protocols

Because GH deficiency cannot be confirmed from random sampling, dynamic provocation testing is performed under medical supervision using GH secretagogues. Two different agents are conventionally required on separate occasions to confirm the diagnosis. Commonly used agents include:

• Insulin tolerance test (ITT) – historically the reference standard, inducing transient hypoglycemia; it is contraindicated in very young children and in patients with seizure disorders or hypoglycemia unawareness.
• Arginine infusion – well tolerated and frequently paired with a second agent.
• Clonidine – an oral alpha-2 agonist widely used in pediatric endocrinology.
• Glucagon – a useful alternative when insulin is contraindicated.
• L-dopa and GHRH–arginine combination – additional validated options, with newer oral GH secretagogues increasingly adopted in updated clinical protocols.

Throughout each test, blood glucose, heart rate, and clinical status must be monitored, and timed specimens are collected for peak GH determination.

Chemiluminescent Immunoassay (CLIA)

Automated chemiluminescent immunoassay is the dominant platform for routine GH, IGF-1, and IGFBP-3 quantification in modern clinical laboratories. Two-site sandwich immunometric formats with acridinium-ester or alkaline-phosphatase labels deliver broad analytical ranges, low detection limits, rapid throughput, and full traceability to international reference materials.

Electrochemiluminescence Immunoassay (ECLIA)

ECLIA platforms using ruthenium-labeled antibodies and tripropylamine-based signal generation provide high sensitivity, excellent precision, and wide dynamic ranges, making them well suited to the low-end quantification required for confirming deficient GH peaks in stimulation testing.

Enzyme-Linked Immunosorbent Assay (ELISA)

Microplate ELISA remains a cost-effective option for smaller laboratories and research studies. For IGF-1 determination, specimens typically require pre-treatment with acid–ethanol extraction or an equivalent dissociation step to release IGF-1 from binding proteins before measurement.

Immunoradiometric Assay (IRMA) and Radioimmunoassay (RIA)

Older isotopic methods have largely been replaced by non-radioactive automated platforms but remain historically important and may still be encountered in resource-limited settings, subject to radiation safety controls.

Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS)

LC-MS/MS is an emerging reference measurement approach for IGF-1, offering high analytical specificity and freedom from antibody-related inter-assay bias. It is increasingly used to harmonize results across immunoassay platforms.

Quality Assurance and Standardization

All methods must be verified and periodically re-verified for precision, accuracy, linearity, and reference intervals in accordance with ISO 15189 and applicable GB laboratory standards. Participation in external quality assessment schemes, lot-to-lot verification of calibrators, and documentation of measurement uncertainty are mandatory elements of a compliant pediatric endocrine testing service. Clinicians should be aware that GH results are not directly interchangeable between immunoassay platforms due to differences in antibody epitope specificity and calibration philosophy, so diagnostic cutoffs must be method-specific.

Applications

Children's growth hormone testing supports a wide spectrum of clinical and research applications in pediatric endocrinology and beyond:

• Diagnosis of growth hormone deficiency – confirming inadequate GH secretion through paired stimulation tests, standardized IGF-1/IGFBP-3 measurement, and supporting auxological assessment.
• Differential diagnosis of short stature – distinguishing GHD from constitutional growth delay, familial short stature, hypothyroidism, celiac disease, Turner syndrome, Prader–Willi syndrome, skeletal dysplasias, and small-for-gestational-age growth failure.
• Eligibility assessment for rhGH therapy – documenting the biochemical and auxological criteria required before initiation of recombinant growth hormone treatment.
• Monitoring of rhGH replacement therapy – serial IGF-1 measurement against target ranges, growth velocity tracking, and surveillance of glucose metabolism and thyroid function during treatment.
• Evaluation of GH excess – investigating rare pediatric gigantism and pituitary hypersecretion using GH suppression protocols following oral glucose administration.
• Nutritional and chronic disease assessment – leveraging IGF-1 as a sensitive marker of nutritional status in chronic illness, chronic kidney disease, and inflammatory conditions affecting growth.
• Clinical research and therapeutic trials – providing standardized pharmacodynamic endpoints for studies of growth-promoting agents conducted by accredited third-party laboratories and hospital reference centers.

FAQ

When should a child be referred for growth hormone testing?

Referral is warranted when a child's height falls more than 2 standard deviations below the mean for age and sex, when growth velocity is persistently below the 25th percentile for skeletal maturity, when the child crosses downward across two major height percentiles on the growth chart, or when risk factors such as hypothalamic–pituitary disease, cranial irradiation, or known genetic syndromes are present.

Why is a random blood test insufficient for diagnosis?

Because GH is secreted in discrete pulses with a short half-life, a healthy child may have an undetectable random GH level between pulses. Diagnosis therefore requires dynamic stimulation testing on two separate occasions, interpreted together with IGF-1, IGFBP-3, growth history, and imaging findings.

Are stimulation tests safe for children?

Yes, when performed in a supervised clinical setting with trained personnel and continuous monitoring. Side effects such as transient drowsiness (clonidine), nausea (arginine), or hypoglycemia (insulin) are predictable and manageable. The insulin tolerance test is avoided in very young children and in those with contraindications such as a history of seizures.

How should parents prepare their child for testing?

Children should fast overnight (water is permitted), avoid strenuous physical activity before the test, and the supervising clinician should be informed of all medications and supplements. For stimulation tests, an intravenous catheter is placed once, so repeated needle sticks are not required during serial sampling.

What does a low peak GH result mean?

A peak stimulated GH below the method-specific cutoff after two independent provocative tests, combined with low IGF-1, reduced growth velocity, and consistent clinical findings, supports a diagnosis of GH deficiency. Pituitary MRI is then typically performed to exclude structural causes before treatment planning.

How long do results take?

Individual hormone assays typically report within 1 to 3 working days after sample receipt. The complete diagnostic workup, including two stimulation sessions, imaging, and specialist interpretation, usually takes several weeks to complete.

Can GH testing be used to monitor treatment?

Yes. During rhGH therapy, IGF-1 is measured periodically and dose-adjusted to maintain values within the age-appropriate target range, alongside monitoring of growth velocity, glucose tolerance, and thyroid function, ensuring both efficacy and safety of long-term treatment.